Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).
Synonyms
Levosalbutamol
Levosalbutamol hydrochloride
R-salbutamol
(R)-salbutamol
(-)-Salbutamol
Levosalbutamol tartrate
Levalbuterol
(-)-Albuterol
Levosalbutamol sulfate
Brand Names
Xopenex HFA
Levalbuterol Inhalation Solution
Levalbuterol Inhalation
Levalbuterol Hydrochloride
Levalbuterol tartrate HFA inhalation
Xopenex
Levalbuterol
Indication
Indicated for the management of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma.
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
